Evidence Hub

Pyroxd1 is essential for murine viability with the homozygous N155S recurrent variant linked to myopathy, muscle hypotrophy and osteopenia

Evesson FJ, Dziaduch G, Yasa J, Best HA, Kiriaev L, Pang I, Jones V, Kettle E et al.

Acta neuropathologica communications, 2026

Abstract

Biallelic variants in PYROXD1 are associated with a life limiting muscle and connective tissue disorder characterised by generalised muscle weakness, breathing and feeding difficulties, distal laxity, hypernasal speech, blue sclera and osteopenia. PYROXD1 encodes an oxidoreductase implicated in mitochondrial function and tRNA ligase activity. Herein we present the first comprehensive suite of mouse models designed to elucidate PYROXD1 redox functions and the underlying pathogenetic basis for PYROXD1 disorders. A LacZ reporter strain reveals ubiquitous expression of Pyroxd1, particularly in the developing head, eye, heart and skin. Complete knockout (KO) of Pyroxd1 resulted in embryonic lethality between ED4.5–E9.5, suggesting Pyroxd1 performs a unique function during embryogenesis that cannot be substituted by other redox enzymes. Skeletal muscle tissue-specific KO, or stage-specific tamoxifen-induced KO during gestation or post-weaning, were viable but not sustainable models. Tamoxifen-inducible KO cell lines derived from these models provide valuable tools for dissecting Pyroxd1 function. Homozygous mice harbouring the recurrent human variant NM_024854.5:c.464A > G;p.(N155S), termed Pyroxd1N155S, phenocopied a severe PYROXD1 disorder, presenting from ~ 10 weeks of age with a progressive myopathy, myofibrillar disorganisation, decreased contractile strength, muscle hypotrophy and osteopenia. Conversely, homozygous Pyroxd1N155G mice, created incidentally during CRISPR…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free